Restoration of mother’s microbial balance as optimal way of preventing innate dysbiosis
UDK: [616‑008.87‑053.3‑02:616‑056.716]‑039.71 | Pages: 20–22 | Read full text | Download PDF
Annotation:
The paper reviews literature devoted to dysbacteriosis likely to occur as a result of moth‑er’s antibiotic treatment and its effects on foetus. First a newborn comes in contact with ambient mi‑crobial flora intranatally, when the foetus passes through the maternal passages. The quantitative and qualitative features of the genital microbiocenosis in a woman in labour are considered to be ones of the crucial factors known to have effects on the formation of baby’s microecological health. The in‑nate dysbiosis is not easy to deal with, and results in an increase of children, and then adults, who suf‑fer from chronic infectious inflammatory diseases. Therefore, it is of high importance to perinatally prevent newborn children’s dysbiosis using new symbiotic drugs that prove to efficiently restore mother’s microbiocenosis.
Links to authors:
V.G. Melnikov
International Science and Technology Center (32–34 Krasnoproletarskaya St. Moscow 127473 Russian Federation)
V.M. Abramov, V.S. Khlebnikov, I.O. Chikileva, R.N. Vasilenko, I.V. Kosarev, V.K. Sakulin
Institute of Engineering Immunology (Lyubuchani Setttl. Chekhovsky District, Moscow Oblast 142380 Russian Federation)
G.R. Ovinova
Perinatal Medical Center (Bld. 1, 24 Sevastopolsky Av. Moscow 117209 Russia),
I.N. Zakharova
Russian Medical Academy of Postgraduate Education (2/1 Barrikadnaya St. Moscow 123995 Russian Federation)
M.V. Kiselevsky
N.I. Blokhin Russian Oncological Research Center (24 Kashirskoye Sh. Moscow 115478 Russian Federation)
T.S. Zaporozhets, T.A. Kuznetsova
Research Institute of Epidemiology and Microbiology of the Siberian Branch of Russian Academy of Sciences (1 Selskaya St. Vladivostok 690087 Russian Federation)
- Ankirskaja A.S. Nonspecific vaginitis, Ginekologija. 2005. No. 4.
P. 15–18.
2. Gracheva N.M. Dysbacterioses and superinfection: causes, diag‑
nosis, treatment, Lechawij vrach. 1998. No. 1. P. 18–21.
3. Kuznecova T.A., Zaporozhec T.S., Besednova N.N. et.al. . Immu‑
nostimulatory and anticoagulant activity of fucoidan from the
brown alga Fucus evanescens, Antibiotiki i himioterapija. 2003.
V. 48, no. 4. P. 11–13.
4. Emergencies in obstetrics and gynecology: diagnosis and treat‑
ment / eds. M. Pirlman, Dzh. Tintinali, P. Din. M.: BINOM,
2009. 499 p.
5. Prilepskaja V.N., Bajramova G.R. Violation vaginal microbiota,
the ways of its correction, Ginekologija. 2007. Vol. 9, No. 4. P.
34–36.
6. Strachunskij L.S. β‑laktomazy of spread spectrum – a rapidly
growing and poorly perceived threat, Klin. mikrobiol. antimikrob.
himioter. 2005. no. 1. P. 2–6.
7. Shabalov N.P. Neonatology. Vol. 2. SPb.: MEDpress, 1997. 640 p.
8. Shenderov B.A. Medical microbial ecology and functional food.
Vol. 1: Mikroflora cheloveka i zhivotnyh i ee funkcii. M: Grant,
1998. 288 p.
9. Jankovskij D.S. The Composition and functions of the microbio‑
cenoses for various human biotopes, Zdorove zhenwiny. 2003. Vol.
16, No. 4. P. 145–158.
10. Favier C., De Vos W. Development of bacterial and bifidobacte‑
rial communities in feces of newborns babies, Anaerobe. 2003.
Vol. 9. P. 219–229.
11. German J.B., Freeman S.F., Lebrilla C., Mills D.A. Human milk
oligosaccharides: Evolution, structures, bioseletivity as substrates
for intestinal bacteria, Personalized Nutrition for the Diverse
Needs of Infants and Children / D.M. Bier, J.B. German, B. Lon‑
nerdahl, eds. Basil: Karger AG, 2008. P. 205–222.
12. Hekmat S., Soltani H., Reid G. Growth and survival of Lactobacil‑
lus reuteri RC‑14 and Lactobacillus ramnosus GR‑1 in yogurt for
use as a functional food, Innovative Food Science and Emerging
Technologies. 2009. Vol. 10. P. 293–296.
13. Ishikava H., Akedo T., Otani T. et al. Randomized trial of dietary
fiber and Lactobacillus casei administration for prevention of
colorectal tumors, Int. J. Cancer. 2005. Vol. 116. P. 762–767.
14. Kalliomaki M., Salminen S., Arvilommi H. et al. Probiotics in
primary prevention of atopic disease: A randomized placebo‑
controlled trial, Lancet. 2001. Vol. 357. P. 1076–1079.
15. Kim T.K., Thomas S.M., Но М. et al. Heterogeneity of vaginal
microbal communities within individuals, J. Clin. Microbiol. 2009.
Vol. 47. P. 1181–1189.
16. Kusaykin M., Bakunina I., Sova V. et al. Structure, biological activ‑
ity, and enzymatic transformation of fucoidans from the brown
seaweeds, Biotechnol. J. 2008. Vol. 3. P. 904–915.
17. Pereira D., Gibson G. Cholesterol Assimilation by Lactic acid
and Bifidobacteria isolated from the human gut, Appl. Environ.
Microbiol. 2002. Vol. 68. P. 4689–4693.
18. Reid G., Bruce A.W., Taylor M. Instillation of Lactobacillus and
stimulation of indigenous organisms to prevent recurrence of
urinary tract infections, Microecol. Ther. 1995. Vol. 23. P. 32–45.
19. Reid G., Bruce A., Fraser N. et al. Oral probiotics can recolve
urogenital infections, FEMS Microbiol Immunol. 2001. Vol. 30.
P. 49–52.
20. Reid G., Dols J., Miller W. Targeting the vaginal microbiota with
probiotics as a means to counteract infections, Curr. Opin. in Clin.
Nutr. and Metabolic Care. 2009. Vol. 12. P. 583–587.
21. Schell M.A., Karmirantzou M., Snel B. et.al. The genome sequence
of Bifidobacterium longum reflects its adaptation to the human
gastrointestinal tract, Proc. Natl. Acad. Sci USA. 2002. Vol. 99.
P. 14412–14427.
22. Sela D.A., Mills D.A. Nursing our microbiota: molecular link‑
ages between bifidobacteria and milk oligosaccharides, Trends
Microbiol. 2010. Vol. 18. P. 298–307.
23. Tutnbaugh P., Ley R., Hamady M. et al. The human microbiome
project, Nature. 2007. Vol. 449. P. 804–810.